Clinical Trial Detail

NCT ID NCT03432676
Title Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

pancreatic ductal adenocarcinoma

pancreatic adenocarcinoma

Therapies

Epacadostat + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST